Novo and Roche-backed Corvus has raised more than $108m in venture funding in just over a year and will spend the IPO proceeds on developiing its immuno-oncology therapies.

Corvus Pharmaceuticals, an immuno-oncology treatment developer backed by pharmaceutical companies Novo and Roche, filed for an initial public offering on Monday that could raise up to $115m.

Founded in 2014, Corvus is working on therapies that will use the body’s immune system to fight cancer cells. It has four immuno-oncology programs in its pipeline and is planning a large expansion cohort trial for its lead candidate, CPI-444, in early 2016.

The IPO proceeds will support a planned phase 1/1b…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?